Endometrial cancer is the most common gynecologic malignancy and the fourth most common cancer among women in the United States.1 In 2018, there will be an estimated 63 230 women diagnosed with endometrial cancer.1 Currently, there is no effective endometrial cancer screening strategy for women who are asymptomatic. Fortunately, endometrial cancer is typically diagnosed in an early stage; 67% of women present with stage I or II disease confined to the uterus, at which point there is a 95% 5-year survival.2